For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 16,567 | 8,613* | 13,737 | 13,145 |
| Credit loss - related party accounts receivable | - | 0* | 0 | 0 |
| General and administrative | 5,897 | 3,786* | 3,966 | 2,703 |
| Total operating expenses | 22,464 | 12,398 | 17,703 | 15,848 |
| Loss from operations | -22,464 | -12,398* | -17,703 | -15,848 |
| Unrealized loss on short-term investments | -13 | -48* | 36 | -7 |
| Interest and dividend income | 889 | 881* | 1,351 | 1,488 |
| Total other income, net | 876 | 832* | 1,387 | 1,481 |
| Net loss | -21,588 | -11,566 | -16,316 | -14,367 |
| Basic EPS | -0.99 | -0.748 | -0.75 | -0.66 |
| Diluted EPS | -0.99 | -0.748 | -0.75 | -0.66 |
| Basic Average Shares | 21,815,995 | 15,469,745 | 21,713,858 | 21,690,275 |
| Diluted Average Shares | 21,815,995 | 15,469,745 | 21,713,858 | 21,690,275 |
Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD)